Linked Life Data

16455511

Source:http://linkedlifedata.com/resource/pubmed/id/16455511

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2006-2-3
pubmed:abstractText
Therapy for renal cell carcinoma has made considerable progress in the past few years. The aims of this review are to update the pathological classification of this tumor and discuss predictive factors for tumor response and survival in the case of metastasis as well as the place of immunotherapy with interleukine-2 and/or interferon alpha . Furthermore, we will review new therapeutic options and current results on allogeneic stem cell transplantation with non-myeloablative conditioning and HLA genoidentical donors. Finally, we will present targeted therapy (antiangiogenic drugs and tyrosine kinase inhibitors) with the mechanisms of action, efficacy and appropriate use in the treatment of metastatic renal cell carcinoma.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1769-6917
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
93
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
91-100
pubmed:dateRevised
2011-4-5
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
[New entities in pathological classification and new therapeutic options in renal cell carcinoma].
pubmed:affiliation
Département d'oncologie médicale, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand. olivier.bay@cjp.fr
pubmed:publicationType
Journal Article, English Abstract, Review